Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coronavirus fibroblast cell therapy - FibroGenesis

Drug Profile

Coronavirus fibroblast cell therapy - FibroGenesis

Latest Information Update: 06 Apr 2020

At a glance

  • Originator FibroGenesis
  • Class Fibroblast cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 01 Apr 2020 FibroGenesis files for patent protection with the USPTO for utilisation of fibroblast cells along with adjuvants for coronavirus
  • 01 Apr 2020 Preclinical trials in COVID-2019 infections in USA (Parenteral)
  • 10 Mar 2020 FibroGenesis files for patent protection with the USPTO for Coronavirus fibroblast cell therapy

Development Overview

Introduction

Human dermal fibroblast (HDFs) based cell therapy is being developed by FibroGenesis for the treatment of COVID-2019 infections and its associated symptom of acute respiratory distress syndrome (ARDS). The therapy addresses acute respiratory distress syndrome by making use of fibroblasts as toll-like receptors which activates fibroblasts as a means to suppress ARDS, while producing inteferons to stimulate anti-viral immunity. Preclinical development is underway in the US.

Patent Information

In April 2020, FibroGenesis filed a US patent No.63/002,134 entitled, "Peptides and Adjuvants for Augmentation of Fibroblast Therapy for Coronavirus." The patent claims include utilisation of fibroblast cells along with adjuvants like peptides and hydroxychloroquine which stimulates the production of natural interferon to suppress the viral infection and corresponding "cytokine storm." [1] .

In March 2020, FibroGenesis filed a US patent No.62 986 339 entitled, "Fibroblast and TLR Activated Fibroblast Treatment of Viral Induced Acute Respiratory Distress Syndrome." The patent claims include utilisation of universal donor cell therapies for treatment of acute respiratory distress syndrome (ARDS) [2] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Fibroblast cell therapies
  • Target Cell
  • Mechanism of Action Cell replacements
  • WHO ATC code

    V03A-X (Other therapeutic products)

  • EPhMRA code

    V3X (All Other Therapeutic Products)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections in patients with ARDS - Preclinical USA Parenteral / unspecified FibroGenesis 01 Apr 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
FibroGenesis Originator USA
FibroGenesis Owner USA

Development History

Event Date Update Type Comment
01 Apr 2020 Patent Information FibroGenesis files for patent protection with the USPTO for utilisation of fibroblast cells along with adjuvants for coronavirus [1] Updated 06 Apr 2020
01 Apr 2020 Phase Change - Preclinical Preclinical trials in COVID-2019 infections in USA (Parenteral) [1] Updated 06 Apr 2020
10 Mar 2020 Patent Information FibroGenesis files for patent protection with the USPTO for Coronavirus fibroblast cell therapy [2] Updated 20 Mar 2020
10 Mar 2020 Phase Change Early research in COVID-2019 infections in USA (Parenteral) [2] Updated 20 Mar 2020

References

  1. FibroGenesis Files Expanded Patent Coverage for its Fibroblast Cell Therapy to treat Coronavirus (COVID-19) ARDS.

    Media Release
  2. FibroGenesis Files Patent Using its Fibroblast Cell Therapy for Coronavirus (COVID-19) ARDS.

    Media Release
Back to top